Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads an article summarizing the review request for Tyvaso DPI to be used in patients with pulmonary arterial hypertension (PH) and PH associated with interstitial lung diseases (ILDs), including those with IPF. Tyvaso is currently approved by the Food and Drug Administration in the US, however, the examination of how an inhaled form of Tyvaso (Tyvaso DPI) might better assist patients with PH and PH-ILDs is currently under way by United Therapeutics.

If you have ILD-induced pulmonary hypertension, have you ever spoken to your doctor about Tyvaso?

Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: https://pulmonaryfibrosisnews.com